NDAORALCAPSULE
Approved
Apr 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
21
Data completeness
6/8 — Strong
RETEVMO (selpercatinib) by Eli Lilly and Company is rearranged during transfection (ret) inhibitors [moa]. Approved for kinase inhibitor [epc]. First approved in 2024.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RETEVMO (selpercatinib) is an oral small-molecule RET kinase inhibitor approved by the FDA on April 10, 2024, developed by Eli Lilly and Company. It selectively targets RearrangedDuringTransfection (RET) mutations, a validated oncology target. The drug is indicated for patients with RET-altered cancers, positioning it as a precision medicine approach in the kinase inhibitor class. It enters a competitive landscape dominated by multi-target kinase inhibitors but offers RET-specific selectivity.
$0.1BPart D
12.9 years to LOEMechanism of Action
Rearranged during Transfection (RET) Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (21)
Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)
Started Jul 2024
13 enrolled
Differentiated Thyroid CancerPediatric CancerCancer+1 more
A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy Participants
Started Jul 2023
28 enrolled
Healthy
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
Started Mar 2023
30 enrolled
Thyroid CancerThyroid CarcinomaMetastatic Thyroid Cancer+3 more
A Study of the Effect of Food on Selpercatinib (LY3527723) in Healthy Participants
Started Apr 2022
46 enrolled
Healthy
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
Started Dec 2021
152 enrolled
Carcinoma, Non-Small-Cell Lung
Worked on RETEVMO at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.